Diamyd Medical
17.44 SEK -3.22%1 investor is following this company
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DMYD B
Daily low / high price
17.38 / 18.1
SEK
Market cap
1.74B SEK
Turnover
4.92M SEK
Volume
278K
Latest videos
Financial calendar
Annual report
2024-10-09
General meeting
2024-12-05
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 12.9 % | 10.3 % |
Bertil Lindkvist | 9.2 % | 7.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Diamyd Medical AB: Diamyd Medical får positiv återkoppling från FDA om potentiellt accelererat godkännande för Diamyd® i typ 1-diabetes
Diamyd Medical AB: Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for the prevention of Type 1 Diabetes
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Diamyd Medical AB: Diamyd Medical erhåller sin andra Fast Track designation för Diamyd® av FDA - för förebyggande av typ 1-diabetes
Impala Nordic: Diamyd Medical - Poddintervju: VD, Ulf Hannelius om fas-3 studien, tillverkningsanläggningen i Umeå och finansieringssituation
Penser Access by Carnegie: Diamyd Medical: En viktig sommar väntar
Diamyd Medical AB: Delårsrapport III 23/24
Diamyd Medical AB: Quarterly Report III 23/24
Diamyd Medical AB: Diamyd Medical uppdaterar om den registreringsgrundande fas 3-studien; kommande interimsanalys och rekrytering
Diamyd Medical AB: Diamyd Medical updates on the registrational Phase 3 trial; upcoming interim analysis and enrollment
Penser Access by Carnegie: Intervju med Diamyd Medical - Carnegie Investment Bank - 24 april 2024
Penser Access by Carnegie: Diamyd Medical - Går en spännande framtid till mötes
Diamyd Medical AB: Diamyd Medical offentliggör slutgiltigt utfall i bolagets företrädesemission
Diamyd Medical AB: Diamyd Medical announces final outcome in the company's rights issue
Diamyd Medical AB: Diamyd Medical offentliggör preliminärt utfall i bolagets företrädesemission
Diamyd Medical AB: Diamyd Medical announces preliminary outcome in the company's rights issue
Penser Access by Carnegie: Intervju med Diamyd Medical - Carnegie Investment Bank - 12 april 2024
Diamyd Medical AB: Rekryteringsmilstolpe har uppnåtts i fas III-studie med Diamyd®
Diamyd Medical AB: Recruitment milestone reached in Diamyd® Phase 3 trial
![Diamyd Medical: Stora steg tagna mot autoimmun diabetes](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/d03cc35e-2ed8-4b12-a882-d542de7957fd.png)